Kymera Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kymera Therapeutics, Inc. (KYMR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-223.86-146.96-154.81-100.2245.59
Depreciation & Amortization7.373.572.982.401.76
Stock Based Compensation55.0143.1235.4824.975.19
Change in Working Capital-23.972.68-34.74-61.92119.93
Change in Accounts Receivable17.82-16.23-2.401.30-1.43
Change in Accounts Payable-0.312.040.250.050.99
Change in Other Working Capital-0.4025.482.306.087.91
Other Operating Activities4.9360.0433.4830.9012.03
Net Cash from Operating Activities-194.50-102.83-153.09-128.9588.13
Investing Activities
Capital Expenditures-12.84-34.482.84-1.609.10
Purchases of Investments-901.23-189.1523.36-98.24-413.49
Sales/Maturities of Investments509.99363.5223.36358.17-413.49
Other Investing Activities13.980.000.000.000.00
Net Cash from Investing Activities-404.08139.8920.52-99.84-422.59
Financing Activities
Debt Repayment-1.58-0.08-1.13-0.850.00
Common Stock Issued596.624.271.15251.53183.15
Other Financing Activities-28.360.00149.83-0.4013.53
Net Cash from Financing Activities608.854.19153.00250.28289.26
Summary
Net Change in Cash10.2741.2520.4321.50-45.20
Cash at Beginning of Period115.7874.5354.0932.5977.79
Cash at End of Period126.05115.7868.4054.0976.02
Free Cash Flow-207.34-137.31-155.92-130.5479.03
Supplemental Disclosures
Interest Paid0.210.160.180.160.12